Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest National Institute for Health and Clinical Excellence Stories

2008-08-25 09:00:26

By Nicola Fenwick CANCER experts have accused a health watchdog of forcing patients to remortgage their homes to pay for treatments freely available in Europe. The group of 26 professors are dismayed at guidance issued by the National Institute for Health and Clinical Excellence (Nice) that deny four kidney cancer drugs on the NHS. Earlier this month, Nice said the drugs + Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) ? were not...

2008-08-24 22:57:41

Home News IN BRIEF *Cancer patients are being forced by a health watchdog to remortgage their homes to pay for treatments freely availably elsewhere in Europe, a group of 26 professors said yesterday. The experts said they were "dismayed" by the National Institute for Health and Clinical Excellence's guidance denying patients four kidney cancer drugs on the NHS and called for "radical change". (c) 2008 Independent, The; London (UK). Provided by ProQuest LLC. All rights Reserved.

2008-08-21 06:01:02

Research and Markets (http://www.researchandmarkets.com/research/7c95b2/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Pricing and Reimbursement News in the Second Quarter of 2008" to their offering. The United States stands in stark contrast to Europe and Japan in terms of the freedom that manufacturers have to set--and increase--the prices of branded drugs in the U S market. However, pharmaceutical companies need to give careful...

2008-08-20 09:00:22

The National Institute for Health and Clinical Excellence, UK has rejected four kidney cancer treatments for use on the National Health Service on grounds that the drugs are not cost effective, according to PharmaTimes. The draft guidance issued by the National Institute for Health and Clinical Excellence (NICE), contends that Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsirolimus) are costly for the treatment of advanced or...

2008-08-18 15:00:16

THE ever-rising drugs bill is one of the biggest headaches for NHS decisionmakers. With some brand-name drugs costing many times as much as a nearidentical formulation under a generic name, doctors have been encouraged to prescribe generics wherever possible. With the annual bill for prescriptions now around GBP1bn, the potential savings are immense. They are not, however, inevitable. Occasionally, brandname drugs can be cheaper, as is now the case with three commonly used medicines which, if...

2008-08-18 09:01:01

THE boss of the NHS's drug approval body today called on local healthcare trusts to end Britain's postcode lottery row. Andrew Dillon, chief executive of the National Institute for Health and Clinical Excellence (NICE), said Primary Care Trusts (PCTs) should be consistent when deciding whether to make funds available for medicines. Mr Dillon told the BBC's Panorama, which airs on BBC1 tonight: "It shouldn't make any difference where you live. "There ought to be a common basis for making...

2008-08-18 09:01:01

By Gavin Engelbrecht THE Government?s drugs approval agency warned last night it might not be able to meet a pledge to speed up decision-making on new treatments. Campaigners and patients have criticised Nice ? the National Institute for Health and Clinical Excellence ? over the time it takes to approve lifegiving drugs. Health Secretary Alan Johnson has pledged to bring decision- making on new drugs down from an average length of two years to only three months. But Andrew Dillon, the...

2008-08-17 18:00:12

A Leading Welsh cancer specialist has condemned plans to prevent patients with advanced kidney cancer from getting specialised drug treatments. The National Institute for Health and Clinical Excellence (Nice) has issued draft guidance rejecting the use of Sutent, Avastin, Nexavar and Torisel on cost grounds, leaving only interferon available to clinicians. John Wagstaff, honorary consultant in medical oncology at the South Wales Cancer Institute in Swansea and director of the Wales Cancer...

2008-08-13 15:00:00

PATIENTS may get independent advice on medicine too costly for the NHS so they can buy it privately. Andrew Dillon, of the National Institute for Health and Clinical Excellence, said: "One of the things we could do well would be to provide independent, objective information for individuals to make up their own mind." Critics say it could lead to a two-tier NHS. Michael Summers, of the Patients Association, said: "Any information is obviously valuable but people would have less need to top...

2008-08-12 00:00:43

By Jeremy Laurance Patients cannot rely on the NHS to save their lives if the cost of doing so is too great, the Government's medicines watchdog has ruled for the first time. The National Institute for Clinical Excellence (Nice) has said the natural impulse to go to the aid of individuals in trouble - as when vast resources are used to save a sailor lost at sea - should not apply to the NHS. The disclosure follows last week's controversial decision by Nice to reject four new drugs for...